Today: 19 March 2026
Subscribe
Browse Category

NSE:ICICIPRULI 7 December 2025 - 12 December 2025

ICICI Prudential AMC IPO Opens Dec 12: GMP Trends, Marquee Pre-IPO Buyers, Anchor Book Details and What Investors Are Watching

ICICI Prudential AMC IPO Opens Dec 12: GMP Trends, Marquee Pre-IPO Buyers, Anchor Book Details and What Investors Are Watching

ICICI Prudential AMC’s IPO opened for subscription in Mumbai on December 12, priced at ₹2,061–₹2,165 per share, with a total offer size of about ₹10,603 crore. The entire issue is an offer-for-sale by Prudential Corporation Holdings, bringing no fresh capital to the AMC. A pre-IPO placement raised around ₹4,800 crore from 26 entities, including the family offices of Azim Premji and Shiv Nadar. Listing is expected on December 19.
12 December 2025
·····
India’s IPO Boom Hits Record ₹1.8 Lakh Crore in 2025 as Wakefit and ICICI Prudential AMC Anchor a Blockbuster December

India’s IPO Boom Hits Record ₹1.8 Lakh Crore in 2025 as Wakefit and ICICI Prudential AMC Anchor a Blockbuster December

India’s IPO fundraising reached ₹1.77–1.8 trillion ($19.6 billion) by 8 December 2025, surpassing the 2024 record of ₹1.73 trillion. Major offerings from Wakefit Innovations and ICICI Prudential AMC are expected to push the total higher. Over 300 companies listed this year, but about half now trade below their issue price. Demand for large IPOs remains strong, with average subscription near 18 times.
9 December 2025
·
RBI MPC December 2025: Rate Cut, Weak Rupee and ICICI Pru AMC IPO — 7 Big Triggers for Indian Stock Market This Week

RBI MPC December 2025: Rate Cut, Weak Rupee and ICICI Pru AMC IPO — 7 Big Triggers for Indian Stock Market This Week

The Sensex closed at 85,712.37 and Nifty 50 at 26,186.45 on Friday, rebounding after the RBI cut its repo rate by 25 basis points to 5.25% and announced a ₹1.45 lakh crore liquidity injection. The rupee traded near ₹90 per US dollar. Investors are watching the RBI’s policy, a major ICICI Prudential AMC IPO, and a US Fed meeting for further direction.
7 December 2025
·

Stock Market Today

  • Soligenix Publishes HyBryte Clinical Data Validating Safety and Efficacy
    March 19, 2026, 2:04 PM EDT. Soligenix (NASDAQ: SNGX), a biopharmaceutical firm targeting rare diseases, reported the publication of clinical trial data on HyBryte (synthetic hypericin) in the peer-reviewed journal Expert Opinion on Investigational Drugs. The summary underscores HyBryte's safety profile, non-mutagenic mechanism, and demonstrated efficacy against cutaneous T-cell lymphoma (CTCL). The data supports HyBryte's potential as a first-line treatment. Soligenix continues its ongoing FLASH2 Phase 3 trial for HyBryte, with an interim analysis slated for Q2 2026. The company focuses on rare disease therapies and vaccine programs underpinned by proprietary technology. This publication bolsters investor confidence as Soligenix advances regulatory efforts toward global commercialization of HyBryte, expanding its pipeline across inflammatory and infectious diseases.
Go toTop